The preventive effect of improving high filtration in subclinical stage on diabetic nephropathy: a prospective, multicenter cohort study
Latest Information Update: 11 Jun 2018
Price :
$35 *
At a glance
- Drugs Dapagliflozin (Primary) ; Losartan (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- 10 Jun 2018 Planned number of patients changed from 80 to 120.
- 10 Jun 2018 Status changed from not yet recruiting to recruiting.
- 10 Jan 2018 New trial record